AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-02	€0.7670	-1.67%	745,893
26-07-01	€0.7800	-11.86%	1,205,200
26-06-30	€0.8850	-1.45%	91,989
26-06-29	€0.8980	+2.75%	192,261
26-06-26	€0.8740	+1.86%	259,326

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-02 EDT			After hours 15:59:58
0.7670 ^EUR	-1.67%		0.7670	0.00%

07-01	AB Science, successful private placement
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

Market Cap	59.7M 68.32M 54.82M 51.12M 96.92M 6.5B 98.56M 660M 256M 3.19B 257M 251M 10.99B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	59.7M 68.32M 54.82M 51.12M 96.92M 6.5B 98.56M 660M 256M 3.19B 257M 251M 10.99B	EV / Sales 2026 *	49.8x	EV / Sales 2027 *	45.9x
Free-Float	67.54%	Yield 2026 *	-	Yield 2027 *	-

07-01	AB Science, successful private placement
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib
06-17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
04-29	AB Science announces successful capital increase
04-28	Air Liquide, Nexans, AB Science... stocks to watch today in Paris

07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ
06-17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
06-09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-01	AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
07-01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
07-01	AB Science, succès d'un placement privé
07-01	AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
07-01	La Bourse s'habitue à tout

1 day	-1.67%
1 week	-11.84%
Current month	-13.33%
1 month	-18.92%
3 months	-37.03%
6 months	-50.07%
Current year	-50.07%

1 week	0.72	0.91
1 month	0.72	0.95
Current year	0.72	1.61
1 year	0.72	1.73
3 years	0.72	4.46
5 years	0.72	16.68
10 years	0.72	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	2001-07-10
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-19	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
21-02-08	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
21-02-01	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-1.67%	-11.84%	-44.90%	-81.69%	68M
MERCK & CO., INC.	+3.34%	+3.28%	+57.25%	+13.32%	310B
MERCK KGAA	+2.08%	+5.28%	+31.23%	-2.67%	71.56B
HALOZYME THERAPEUTICS, INC.	+3.17%	+9.38%	+47.57%	+115.43%	9.13B
KYOWA KIRIN CO., LTD.	+2.59%	+2.99%	+7.96%	-1.24%	8.27B
SK BIOPHARMACEUTICALS CO., LTD.	-0.12%	0.00%	-6.28%	+7.05%	4.38B
BETTA PHARMACEUTICALS CO., LTD.	-1.10%	+14.01%	+11.59%	+39.91%	4.21B
YUHAN CORPORATION	-0.57%	-3.04%	-33.17%	+21.86%	3.39B
SUPERNUS PHARMACEUTICALS, INC.	+1.35%	+7.37%	+49.83%	+60.70%	2.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.31%	+6.66%	+16.30%	-21.65%	2.24B
Average	+0.56%	+5.32%	+13.74%	+15.10%	41.56B
Weighted average by Cap.	+2.34%	+6.70%	+49.42%	+12.90%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.1M 1.03M 1.95M 131M 1.98M 13.27M 5.14M 64.13M 5.16M 5.04M 221M	1.3M 1.49M 1.19M 1.11M 2.11M 142M 2.15M 14.37M 5.57M 69.47M 5.59M 5.46M 239M
Net income	-	-
Net Debt	-	-